The dual GCGR/GLP‐1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection

202412 citationsJournal Articlehybrid Open Access

Authors

Leo Thomas · Boehringer Ingelheim (Germany)

Eric Martel · Boehringer Ingelheim (Germany)

Wolfgang Rist · Boehringer Ingelheim (Germany)

Ingo Uphues · Boehringer Ingelheim (Germany)

Dieter Hamprecht · Boehringer Ingelheim (Italy)

Heike Neubauer · Boehringer Ingelheim (Germany)

Robert Augustin

Abstract

Survodutide was selected as the clinical candidate based on its balanced dual GCGR/GLP-1R pharmacology, engaging the GCGR for robust body weight-lowering efficacy exceeding that of selective GLP-1R agonists, while achieving antidiabetic efficacy that was comparable to selective GLP-1R agonism. Survodutide is currently being investigated in Phase 3 clinical trials in people living with obesity.

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Obesity and Metabolism

Volume 26, Issue 6, pp. 2368-2378

DOI: 10.1111/dom.15551

Field-Weighted Citation Impact: 4.56